|
1
|
Bilbao-Aldaiturriaga N, Askaiturrieta Z,
Granado-Tajada I, Goričar K, Dolžan V, Garcia-Miguel P, Garcia de
Andoin N, Martin-Guerrero I and Garcia-Orad A; For The Slovenian
Osteosarcoma Study Group: A systematic review and meta-analysis of
MDM2 polymorphisms in osteosarcoma susceptibility. Pediatr Res.
80:472–479. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson PM, Bielack SS, Gorlick RG,
Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E,
Pápai Z, et al: A phase II study of clinical activity of SCH 717454
(robatumumab) in patients with relapsed osteosarcoma and Ewing
sarcoma. Pediatr Blood Cancer. 63:1761–1770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nikitovic D, Kavasi RM, Berdiaki A,
Papachristou DJ, Tsiaoussis J, Spandidos DA, Tsatsakis AM and
Tzanakakis GN: Parathyroid hormone/parathyroid hormone-related
peptide regulate osteosarcoma cell functions: Focus on the
extracellular matrix (Review). Oncol Rep. 36:1787–1792. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liao LQ, Yan HH, Mai JH, Liu WW, Li H, Guo
ZM, Zeng ZY and Liu XK: Radiation-induced osteosarcoma of the
maxilla and mandible after radiotherapy for nasopharyngeal
carcinoma. Chin J Cancer. 35:892016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bami M, Mavrogenis AF, Angelini A,
Milonaki M, Mitsiokapa E, Stamoulis D and Soucacos PN: Bone
morphogenetic protein signaling in musculoskeletal cancer. J Cancer
Res Clin Oncol. 142:2061–2072. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Angelini A, Mavrogenis AF, Trovarelli G,
Ferrari S, Picci P and Ruggieri P: Telangiectatic osteosarcoma: A
review of 87 cases. J Cancer Res Clin Oncol. 142:2197–2207. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Z, Li B, Ren Y and Ye Z: T-cell-based
immunotherapy for osteosarcoma: Challenges and opportunities. Front
Immunol. 7:3532016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Osasan S, Zhang M, Shen F, Paul PJ, Persad
S and Sergi C: Osteogenic sarcoma: A 21st century review.
Anticancer Res. 36:4391–4398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nataraj V, Rastogi S, Khan SA, Sharma MC,
Agarwala S, Vishnubhatla S and Bakhshi S: Prognosticating
metastatic osteosarcoma treated with uniform chemotherapy protocol
without high dose methotrexate and delayed metastasectomy: A single
center experience of 102 patients. Clin Transl Oncol. 18:937–944.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu K, Dai HB and Qiu ZL: mTOR signaling in
osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol
Rep. 36:1219–1225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS,
Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, et al: Higher
gemcitabine dose was associated with better outcome of osteosarcoma
patients receiving gemcitabine-docetaxel chemotherapy. Pediatr
Blood Cancer. 63:1552–1556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kebudi R, Ozger H, Kızılocak H, Bay SB and
Bilgiç B: Osteosarcoma after hematopoietic stem cell
transplantation in children and adolescents: Case report and review
of the literature. Pediatr Blood Cancer. 63:1664–1666. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adamopoulos C, Gargalionis AN, Piperi C
and Papavassiliou AG: Recent advances in mechanobiology of
osteosarcoma. J Cell Biochem. 118:232–236. 2017. View Article : Google Scholar
|
|
14
|
Li CJ, Liu XZ, Zhang L, Chen LB, Shi X, Wu
SJ and Zhao JN: Advances in bone-targeted drug delivery systems for
neoadjuvant chemotherapy for osteosarcoma. Orthop Surg. 8:105–110.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abarrategi A, Tornin J, Martinez-Cruzado
L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini
N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-origin,
cancer stem cells, and targeted therapies. Stem Cells Int.
2016:36317642016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang SD, Li HY, Li BH, Xie T, Zhu T, Sun
LL, Ren HY and Ye ZM: The role of CTLA-4 and PD-1 in anti-tumor
immune response and their potential efficacy against osteosarcoma.
Int Immunopharmacol. 38:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ding L, Congwei L, Bei Q, Tao Y, Ruiguo W,
Heze Y, Bo D and Zhihong L: mTOR: An attractive therapeutic target
for osteosarcoma? Oncotarget. 7:50805–50813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ravindra VM, Eli IM, Schmidt MH and
Brockmeyer DL: Primary osseous tumors of the pediatric spinal
column: Review of pathology and surgical decision making. Neurosurg
Focus. 41:E32016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hurley C, McCarville MB, Shulkin BL, Mao
S, Wu J, Navid F, Daw NC, Pappo AS and Bishop MW: Comparison of
(18) F-FDG-PET-CT and bone scintigraphy for evaluation of osseous
metastases in newly diagnosed and recurrent osteosarcoma. Pediatr
Blood Cancer. 63:1381–1386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kulcheski FR, Christoff AP and Margis R:
Circular RNAs are miRNA sponges and can be used as a new class of
biomarker. J Biotechnol. 238:42–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stope MB, Koensgen D, Weimer J, Paditz M,
Burchardt M, Bauerschlag D and Mustea A: The future therapy of
endometrial cancer: microRNA's functionality, capability, and
putative clinical application. Arch Gynecol Obstet. 294:889–895.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang Q, Xu T, Wu C, Zhou S and Sun H:
Biotargets in neural regeneration. Biotarget. 1:62017. View Article : Google Scholar
|
|
23
|
Wang DD, Chen X, Yu DD, Yang SJ, Shen HY,
Sha HH, Zhong SL, Zhao JH and Tang JH: miR-197: A novel biomarker
for cancers. Gene. 591:313–319. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang C, Zheng SD, Wu HJ and Chen SJ:
Regulatory mechanisms of the molecular pathways in fibrosis induced
by microRNAs. Chin Med J (Engl). 129:2365–2372. 2016. View Article : Google Scholar
|
|
25
|
Lee K and Ferguson LR: MicroRNA biomarkers
predicting risk, initiation and progression of colorectal cancer.
World J Gastroenterol. 22:7389–7401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matin F, Jeet V, Clements JA, Yousef GM
and Batra J: MicroRNA theranostics in prostate cancer precision
medicine. Clin Chem. 62:1318–1333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rajasekaran S, Pattarayan D, Rajaguru P,
Sudhakar Gandhi PS and Thimmulappa RK: MicroRNA regulation of acute
lung injury and acute respiratory distress syndrome. J Cell
Physiol. 231:2097–2106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Connelly CM, Moon MH and Schneekloth JS
Jr: The emerging role of RNA as a therapeutic target for small
molecules. Cell Chem Biol. 23:1077–1090. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Li J, Sun X, Chen J, Sun X, Zheng J
and Chen R: MicroRNA-27a functions as a tumor suppressor in renal
cell carcinoma by targeting epidermal growth factor receptor. Oncol
Lett. 11:4217–4223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen S, Sun YY, Zhang ZX, Li YH, Xu ZM and
Fu WN: Transcriptional suppression of microRNA-27a contributes to
laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin
pathway. Oncotarget. 8:14708–14718. 2017.PubMed/NCBI
|
|
31
|
Jiang H, Zhang G, Wu JH and Jiang CP:
Diverse roles of miR-29 in cancer (review). Oncol Rep.
31:1509–1516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kollinerova S, Vassanelli S and Modriansky
M: The role of miR-29 family members in malignant hematopoiesis.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 158:489–501.
2014.PubMed/NCBI
|
|
33
|
Pan W, Wang H, Jianwei R and Ye Z:
MicroRNA-27a promotes proliferation, migration and invasion by
targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem.
33:402–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou L, Liang X, Zhang L, Yang L, Nagao N,
Wu H, Liu C, Lin S, Cai G and Liu J: miR-27a-3p functions as an
oncogene in gastric cancer by targeting BTG2. Oncotarget.
7:51943–51954. 2016.PubMed/NCBI
|
|
35
|
Hu D and Shilatifard A: Epigenetics of
hematopoiesis and hematological malignancies. Genes Dev.
30:2021–2041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Forloni M, Gupta R, Nagarajan A, Sun LS,
Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, et
al: Oncogenic EGFR represses the TET1 DNA demethylase to induce
silencing of tumor suppressors in cancer cells. Cell Reports.
16:457–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li L, Li C, Mao H, Du Z, Chan WY, Murray
P, Luo B, Chan AT, Mok TS, Chan FK, et al: Epigenetic inactivation
of the CpG demethylase TET1 as a DNA methylation feedback loop in
human cancers. Sci Rep. 6:265912016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
39
|
Zhou K, Liu M and Cao Y: New insight into
microRNA functions in cancer: Oncogene-microRNA-tumor suppressor
gene network. Front Mol Biosci. 4:462017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaur S, Lotsari-Salomaa JE,
Seppänen-Kaijansinkko R and Peltomäki P: MicroRNA methylation in
colorectal cancer. Adv Exp Med Biol. 937:109–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tang W, Zhu J, Su S, Wu W, Liu Q, Su F and
Yu F: miR-27 as a prognostic marker for breast cancer progression
and patient survival. PLoS One. 7:e517022012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tanaka K, Miyata H, Sugimura K, Fukuda S,
Kanemura T, Yamashita K, Miyazaki Y, Takahashi T, Kurokawa Y,
Yamasaki M, et al: miR-27 is associated with chemoresistance in
esophageal cancer through transformation of normal fibroblasts to
cancer-associated fibroblasts. Carcinogenesis. 36:894–903. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Colangelo T, Polcaro G, Ziccardi P, Pucci
B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A,
Santopaolo M, et al: Proteomic screening identifies calreticulin as
a miR-27a direct target repressing MHC class I cell surface
exposure in colorectal cancer. Cell Death Dis. 7:e21202016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou S, Huang Q, Zheng S, Lin K, You J and
Zhang X: miR-27a regulates the sensitivity of breast cancer cells
to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol.
37:6837–6845. 2016. View Article : Google Scholar
|
|
45
|
Mirabello L, Koster R, Moriarity BS,
Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou
OA, Largaespada D, et al: A genome-wide scan identifies variants in
NFIB associated with metastasis in patients with osteosarcoma.
Cancer Discov. 5:920–931. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lv YF, Dai H, Yan GN, Meng G, Zhang X and
Guo QN: Downregulation of tumor suppressing STF cDNA 3 promotes
epithelial-mesenchymal transition and tumor metastasis of
osteosarcoma by the Wnt/GSK-3β/β-catenin/Snail signaling pathway.
Cancer Lett. 373:164–173. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu Y and Jiang M: The revolution of lung
cancer treatment: From vaccines, to immune checkpoint inhibitors,
to chimeric antigen receptor T therapy. Biotarget. 1:72017.
View Article : Google Scholar
|
|
48
|
Sun L and Fang J: Epigenetic regulation of
epithelial-mesenchymal transition. Cell Mol Life Sci. 73:4493–4515.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tufekci KU, Oner MG, Genc S and Genc K:
MicroRNAs and multiple sclerosis. Autoimmune Dis.
2011:8074262010.PubMed/NCBI
|
|
50
|
Lu HG, Zhan W, Yan L, Qin RY, Yan YP, Yang
ZJ, Liu GC, Li GQ, Wang HF, Li XL, et al: TET1 partially mediates
HDAC inhibitor-induced suppression of breast cancer invasion. Mol
Med Rep. 10:2595–2600. 2014. View Article : Google Scholar : PubMed/NCBI
|
